BIOTRONIK Awarded Group Purchasing Contract for Coronary Products from Vizient Contract Offers Increased Savings to More than Half of Nation’s Healthcare Organizations for BIOTRONIK’s Coronary Products Including the Orsiro Drug Eluting Stent

BIOTRONIK today announced that it has received a group purchasing contract from Vizient, Inc., the largest, member-driven, healthcare performance improvement company in the United States. The contract increases access to BIOTRONIK’s proven, trusted vascular intervention solutions — drug eluting stents (DES), bare metal stents, balloons and guidewires — for Vizient members, which includes more than half of the nation’s healthcare organizations.

BIOTRONIK’s ultrathin strut DES, Orsiro^®, received FDA approval in February 2019 and is the contract’s centerpiece.

“Orsiro is changing the standard of care. The recently published BIOFLOW-V three-year data clearly shows that Orsiro continues to outperform,” said Dr. David Hayes, Chief Medical Officer of BIOTRONIK Inc. “Access to innovative, proven technologies is how patient care is improved. With the Vizient contract in place, physicians can choose Orsiro at enhanced savings and hopefully more patients can experience the benefits.”

The Orsiro system provides ultrathin strut stents without compromising radial strength, as well as a low crossing profile for easier lesion cross in complex PCI.¹ Three-year results from BIOFLOW V show Orsiro’s ability to clinically outperform other ultrathin DES across the most important three-year secondary endpoints, including TLF rate, ischemia-driven TLR rate, and rate of TV-MI².

It is available in 52 sizes, ranging from 2.25 to 4.0 mm in diameter, and lengths up to 40 mm, the longest DES available in the United States.³

Vizient’s diverse membership base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers, and represents more than $100 billion in annual purchasing volume.

“Our contract with Vizient is further proof that BIOTRONIK’s innovative portfolio of cardiovascular solutions are gaining traction throughout the US,” said Ryan Walters, President at BIOTRONIK Inc. “Hospitals recognize the benefits of innovation and our ability to help improve care while managing costs. We’re a trusted resource and we’re working to shake things up in the market with a commitment to improving healthcare.”

References

^{Orsiro is a trademark or registered trademark of the BIOTRONIK Group of Companies.}

^{1 BIOTRONIK data on file.}

^{2 Kandzari D et al. J Am Coll Cardiol. Cardiovasc Interven. 2020, doi: 10.1016/j.jcin.2020.02.019.}

^{3 As per IFU.}